ALZN · Alzamend Neuro, Inc.
The AI's read
ALZN no longer has an active bipolar study, and the FDA questioned whether its current studies could show that the drug works. The completed healthy-subject study and expected results in December offer useful information, but they do not settle the FDA’s concern. ALZN plans to ask the FDA about a revised plan, possibly a Phase III bipolar study. The FDA’s response is not expected until the end of the second quarter of 2027, so the next testing steps remain uncertain.